Trust Co. of Vermont Sells 2,823 Shares of CVS Health Corporation $CVS

Trust Co. of Vermont lessened its stake in shares of CVS Health Corporation (NYSE:CVS) by 6.5% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 40,822 shares of the pharmacy operator’s stock after selling 2,823 shares during the quarter. Trust Co. of Vermont’s holdings in CVS Health were worth $2,816,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of CVS. Goldman Sachs Group Inc. raised its position in CVS Health by 87.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 9,927,650 shares of the pharmacy operator’s stock valued at $672,598,000 after purchasing an additional 4,632,530 shares during the last quarter. Dodge & Cox raised its position in CVS Health by 4.8% in the 1st quarter. Dodge & Cox now owns 73,459,122 shares of the pharmacy operator’s stock valued at $4,976,856,000 after purchasing an additional 3,353,223 shares during the last quarter. Nuveen LLC bought a new position in CVS Health in the 1st quarter valued at $204,421,000. Assenagon Asset Management S.A. raised its position in CVS Health by 310.8% in the 1st quarter. Assenagon Asset Management S.A. now owns 3,523,824 shares of the pharmacy operator’s stock valued at $238,739,000 after purchasing an additional 2,666,029 shares during the last quarter. Finally, Invesco Ltd. raised its position in CVS Health by 13.2% in the 1st quarter. Invesco Ltd. now owns 20,413,853 shares of the pharmacy operator’s stock valued at $1,383,039,000 after purchasing an additional 2,375,764 shares during the last quarter. Institutional investors own 80.66% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have issued reports on the company. Cowen reiterated a “buy” rating on shares of CVS Health in a research report on Monday, August 4th. Wolfe Research lifted their target price on CVS Health from $80.00 to $85.00 and gave the company an “outperform” rating in a research note on Monday, September 22nd. Robert W. Baird raised CVS Health from a “neutral” rating to an “outperform” rating and lifted their target price for the company from $71.00 to $82.00 in a research note on Thursday, August 14th. UBS Group raised CVS Health from a “neutral” rating to a “buy” rating and lifted their target price for the company from $67.00 to $79.00 in a research note on Monday, August 18th. Finally, Zacks Research cut CVS Health from a “strong-buy” rating to a “hold” rating in a research note on Monday, September 8th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $78.25.

Insiders Place Their Bets

In other news, Director Anne A. Finucane sold 7,500 shares of the business’s stock in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $71.02, for a total value of $532,650.00. Following the sale, the director directly owned 22,156 shares in the company, valued at $1,573,519.12. The trade was a 25.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 1.22% of the company’s stock.

CVS Health Stock Performance

CVS stock opened at $75.31 on Wednesday. The business’s 50-day moving average price is $69.70 and its two-hundred day moving average price is $67.13. The company has a current ratio of 0.80, a quick ratio of 0.62 and a debt-to-equity ratio of 0.74. The firm has a market cap of $95.52 billion, a PE ratio of 21.04, a P/E/G ratio of 0.83 and a beta of 0.62. CVS Health Corporation has a 1-year low of $43.56 and a 1-year high of $77.34.

CVS Health (NYSE:CVS) last posted its earnings results on Thursday, July 31st. The pharmacy operator reported $1.81 earnings per share for the quarter, topping the consensus estimate of $1.46 by $0.35. The firm had revenue of $98.92 billion for the quarter, compared to analyst estimates of $94.87 billion. CVS Health had a return on equity of 10.51% and a net margin of 1.17%.The company’s revenue for the quarter was up 8.4% on a year-over-year basis. During the same period in the previous year, the company posted $1.83 earnings per share. CVS Health has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, research analysts forecast that CVS Health Corporation will post 5.89 earnings per share for the current year.

CVS Health Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 3rd. Shareholders of record on Thursday, October 23rd will be issued a dividend of $0.665 per share. The ex-dividend date is Thursday, October 23rd. This represents a $2.66 annualized dividend and a yield of 3.5%. CVS Health’s payout ratio is currently 74.30%.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.